JUN (Ab-73) Antibody

What is JUN (Ab-73) Antibody and what does it target?

JUN (Ab-73) antibody is a rabbit polyclonal antibody that detects the endogenous level of total c-Jun protein, specifically targeting a peptide sequence around amino acids 71-75 (L-A-S-P-E) derived from human c-Jun . This antibody recognizes c-Jun (also known as Transcription factor AP-1 subunit Jun), which functions as a critical transcription factor that binds to the AP-1 consensus motif 5'-TGA[GC]TCA-3' . The c-Jun protein (approximately 43 kDa) is involved in various cellular processes including transcriptional regulation, cell death signaling, and steroidogenic gene expression .

What applications is JUN (Ab-73) Antibody validated for?

The antibody has been validated for multiple research applications with specific recommended dilutions:

Research validation includes testing with multiple cell lines such as 3T3, HUVEC, and 293 cells, as evidenced by Western blot analyses . The antibody has been cited in multiple publications, indicating reliability in research settings.

What species reactivity has been confirmed for this antibody?

JUN (Ab-73) antibody has been verified to react with samples from the following species :

• Human

• Mouse

• Rat

This cross-reactivity makes it valuable for comparative studies across these mammalian models in research investigating conserved c-Jun functions and signaling pathways.

How should researchers optimize JUN (Ab-73) Antibody use in Western blotting?

For optimal Western blot results with JUN (Ab-73) antibody, researchers should:

• Use freshly prepared protein extracts from relevant cell lines (such as 3T3, HUVEC, or 293 cells)

• Apply the antibody at the recommended dilution of 1:500-1:1000

• Include appropriate positive controls (cell lines known to express c-Jun)

• Verify signal specificity using blocking peptides or knockout/knockdown samples

• Consider the anticipated molecular weight of c-Jun (~43 kDa) when evaluating results

• For phosphorylation-specific studies, compare with phospho-specific antibodies such as anti-c-Jun (phospho S73)

Optimal detection may require titration of antibody concentration based on your specific sample types and expression levels.

What is the recommended protocol for immunohistochemistry with JUN (Ab-73) Antibody?

For immunohistochemistry applications with formalin-fixed, paraffin-embedded (FFPE) sections:

• Deparaffinize and rehydrate tissue sections using standard protocols

• Perform antigen retrieval (heat-induced epitope retrieval recommended)

• Block endogenous peroxidase activity with hydrogen peroxide solution

• Apply protein blocking solution to reduce non-specific binding

• Incubate with JUN (Ab-73) antibody at 1:50-1:100 dilution

• Use appropriate detection system (e.g., HRP-conjugated secondary antibody)

• Develop with DAB substrate and counterstain with hematoxylin

• Include positive and negative controls for validation

Optimization might be required for specific tissue types, as fixation conditions may affect epitope accessibility.

How should researchers validate antibody specificity for c-Jun detection?

Comprehensive validation strategies for JUN (Ab-73) antibody should include:

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide (L-A-S-P-E) before application to demonstrate signal reduction

• Genetic knockdown/knockout controls: Compare signals between wild-type and c-Jun-depleted samples

• Cross-validation: Compare results with alternative antibodies targeting different epitopes of c-Jun

• Multiple detection methods: Confirm findings using complementary techniques (e.g., IF, IHC, WB)

• Cell treatment controls: Use samples from cells treated with stimuli known to modulate c-Jun expression (e.g., stress inducers)

• Molecular weight verification: Confirm band appears at the expected ~43 kDa position

These validation approaches ensure experimental rigor and enhance result reliability.

How can JUN (Ab-73) Antibody be used to investigate c-Jun's role in transcriptional regulation?

JUN (Ab-73) antibody can be employed in several advanced applications to study c-Jun's transcriptional functions:

• Chromatin Immunoprecipitation (ChIP): To identify genomic regions bound by c-Jun, particularly in the context of AP-1 binding sites (5'-TGA[GC]TCA-3')

• Co-immunoprecipitation (Co-IP): To isolate c-Jun and identify interacting proteins, such as FOS family members that form AP-1 complexes

• Proximity ligation assays (PLA): To visualize and quantify c-Jun interactions with other transcription factors in situ

• Reporter gene assays: Combined with c-Jun overexpression or knockdown to assess functional impact on target gene expression

• Immunofluorescence co-localization: To examine nuclear translocation and co-localization with transcriptional machinery

When investigating c-Jun's role in specific pathways, consider concurrent analysis with related factors such as FOSB in T-cell activation-induced cell death or NR5A1 in steroidogenic gene expression .

What considerations exist when comparing phosphorylated versus total c-Jun detection?

Researchers studying c-Jun activation states should consider:

• Distinct antibody requirements: For phosphorylation-specific detection, use dedicated phospho-S73 antibodies rather than the total c-Jun (Ab-73) antibody

• Stimulus-response experiments: c-Jun is phosphorylated at Ser73 in response to various stimuli, including growth factors and stress

• Temporal dynamics: Design time-course experiments to capture the kinetics of phosphorylation/dephosphorylation

• Parallel detection: Use both phospho-specific and total c-Jun antibodies on parallel samples to calculate phosphorylation ratios

• Phosphatase controls: Include samples treated with phosphatase inhibitors to preserve phosphorylation states

• Functional correlations: Correlate phosphorylation status with functional readouts (e.g., target gene expression)

This multi-faceted approach allows for comprehensive analysis of c-Jun activity states in complex signaling networks.

How can JUN (Ab-73) Antibody be utilized to study c-Jun in disease models?

The JUN (Ab-73) antibody can provide valuable insights into c-Jun's role in various disease contexts:

• Cancer research: Investigate c-Jun's involvement in colorectal cancer by analyzing its binding to the USP28 promoter

• Viral infection models: Study c-Jun's interaction with viral proteins, such as its binding to BZLF1 Z promoter during Epstein-Barr virus infection

• Inflammatory conditions: Examine c-Jun expression in tissue sections from inflammatory disease models

• Cell death pathway analysis: Explore c-Jun's contribution to activation-induced cell death of T cells through regulation of FASLG/CD95L

• Signaling pathway perturbations: Combine with inhibitors of relevant pathways (e.g., MAPK) to dissect regulatory mechanisms

When designing such studies, include appropriate disease and control tissue panels with consistent processing methods to ensure comparable results.

How should researchers interpret multiple bands in Western blots using JUN (Ab-73) Antibody?

When multiple bands appear in Western blots using JUN (Ab-73) antibody, consider these interpretations:

• Expected c-Jun band: The primary band should appear at approximately 43 kDa

• Post-translational modifications: Higher molecular weight bands may represent phosphorylated, sumoylated, or ubiquitinated forms of c-Jun

• Proteolytic fragments: Lower molecular weight bands could indicate proteolytic cleavage products

• Isoforms: Alternative splicing may generate c-Jun variants of different sizes

• Cross-reactivity: Some bands may represent related AP-1 family members with sequence similarity

• Non-specific binding: Particularly in complex tissue lysates, some bands may be non-specific

To resolve ambiguities:

• Use purified recombinant c-Jun as a positive control

• Compare band patterns with those obtained using other validated c-Jun antibodies

• Perform peptide competition assays to identify specific versus non-specific signals

• Consider sample preparation conditions that might affect protein integrity

What are common sources of variability when using JUN (Ab-73) Antibody and how can they be addressed?

Several factors can contribute to experimental variability:

Implementing these strategies will enhance reproducibility and minimize experiment-to-experiment variation.

How can researchers distinguish between technical artifacts and genuine biological signals?

To differentiate between technical artifacts and true biological signals:

• Include appropriate controls:

  • Positive control (known c-Jun-expressing sample)

  • Negative control (c-Jun knockout/knockdown)

  • Secondary antibody-only control (to assess background)

  • Isotype control (to assess non-specific binding)

• Perform biological replicates: Confirm results across multiple independent experiments

• Use complementary detection methods: Verify findings using alternative techniques (e.g., IF, IHC, WB)

• Evaluate signal patterns: Biologically relevant signals should show expected subcellular localization (predominantly nuclear for c-Jun) and expression patterns consistent with known biology

• Dose-response and kinetic analyses: True biological signals should respond predictably to stimuli known to affect c-Jun expression or activity

• Cross-validation with functional assays: Correlate antibody-based detection with functional readouts of c-Jun activity (e.g., reporter assays, target gene expression)

This multi-faceted approach helps establish confidence in experimental observations.

When should researchers choose JUN (Ab-73) Antibody versus phospho-specific c-Jun antibodies?

The choice between total and phospho-specific antibodies depends on research questions:

For comprehensive studies of c-Jun biology, researchers should consider using both antibody types to distinguish between expression and activation-related changes.

What are the methodological differences between studying c-Jun in different experimental systems?

Adaptation of methods for different experimental systems requires consideration of several factors:

Method optimization for specific experimental systems will maximize detection sensitivity and specificity.

How does the structural relationship between antibody and epitope influence experimental outcomes?

Understanding the structural aspects of antibody-epitope interaction can inform experimental design:

• Epitope accessibility: The JUN (Ab-73) antibody targets a peptide sequence around amino acids 71-75 (L-A-S-P-E) , which may be affected by protein folding or interactions with other molecules

• Binding mechanisms: As described in search result , antibody binding can follow different modes:

  • Lock and key model: Minimal conformational changes

  • Induced fit: Extensive conformational changes upon binding

  • Conformational selection: Binding depends on pre-existing conformational states

• Impact on experimental applications:

  • For Western blotting: Denaturing conditions expose the epitope, enhancing detection

  • For immunoprecipitation: Native conditions preserve protein-protein interactions but may affect epitope accessibility

  • For IHC/ICC: Fixation and antigen retrieval methods influence epitope exposure

• Phosphorylation proximity effects: The epitope (aa 71-75) is close to the Ser73 phosphorylation site , potentially affecting antibody binding in phosphorylated states

Understanding these structural considerations helps researchers select appropriate experimental conditions and interpret results appropriately.